
HOME		SEARCH		RSS FEED		SUBSCRIBE

Search Results - nb1xxx

11 Results

Sort By:

Engineering Neural Stem Cells Using Homologous Recombination

Methods for modifying the genome of a Neural Stem Cell (NSC) are disclosed. Also, methods for differentiating NSCs into neurons and glia are described. NSCs are multipotent, self-renewing cells found in the central nervous system, capable of differentiating into neurons and glia. NSCs can be generated efficiently from pluripotent stem cells (PSCs)...

Published: 7/30/2024 | Inventor(s): Mahendra Rao, Jizhong Zou, Raymond Funahashi, Nasir Malik

Keywords(s): Cells, EFFECTOR, Gene, Listed LPM Vepa as of 4/15/2015, NB1XXX, Nucleases, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SOMATIC, TAl, Targeting, VEXXXX, WIXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Neurology

Diffusion Through Skull as Route of Delivery for Treatment of Brain Injury and Disease

Traumatic Brain injury (TBI) often results from head impact and is a major cause of death and disability. Brain injuries vary in severity and can be associated with hemorrhaging, swelling, inflammation, and death of brain tissue. Inventors at NINDS developed a novel approach to treating brain injuries that involves transcranial application of small...

Published: 7/25/2024 | Inventor(s): Theodore Roth, Dorian McGavern

Keywords(s): AB3DXX, AB3XXX, ABXXXX, AXXXXX, brain, Delivery, diffusion, Disease, INJURY, NB1JXX, NB1XXX, NBXXXX, NXXXXX, Route, Skull, TREATMENTS

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Neurology, Application > Therapeutics

Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis

The invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple...

Published: 7/25/2024 | Inventor(s): Erika Englund, Juan Marugan, Samarjit Patnaik, Hee-Yong Kim

Keywords(s): Derivatives, Development, Discovery, Docosahexaenoylamide, Growth, IB6XXX, IBXXXX, IXXXXX, Listed LPM Vepa as of 4/15/2015, NB1FXX, NB1HXX, NB1XXX, NBXXXX, Neurons, NXXXXX, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Promote, That, VEXXXX, YAXXXX, YBXXXX, YFXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Neurology, Application > Diagnostics, TherapeuticArea > Reproductive Health, Application > Research Materials, Application > Vaccines, Application > Therapeutics

SIRT2 Inhibitors as Novel Therapeutics for Myocardial Infarction and Ischemic Stroke and to Prevent Necrosis

Sirtuin 2 (SIRT2) inhibitors to reduce necrosis and, thereby, as novel therapeutics to treat ischemic stroke and myocardial infarction. Accumulating evidence indicates that programmed necrosis plays a critical role in cell death during ischemia-reperfusion. NIH investigators have shown that the NAD-dependent deacetylase SIRT2 binds constitutively...

Published: 4/8/2024 | Inventor(s): Toren Finkel, Nisha Narayan

Keywords(s): Against, AGK2, deacetylase, IB1FXX, IB1XXX, IBXXXX, inhibitor, IXXXXX, NAD-dependent, NB1HXX, NB1XXX, NBXXXX, NECROSIS, NXXXXX, PROTECTS, Sirt2

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Cardiology, TherapeuticArea > Neurology

Axon Regeneration After Brain or Spinal Cord Injury

The invention is directed to modification of a particular sugar by the enzyme arylsulfatase B (ARSB), which results in axon regeneration. Following traumatic brain or spinal cord injury, glial scars prevent regeneration of axons. Chondroitin sulfate proteoglycans (CSPGs) are major components of glial scars. CSPGs are made of a protein core containing...

Published: 7/25/2024 | Inventor(s): Yasuhiro Katagiri, Herbert Geller

Keywords(s): AFTER, Arylsulfatase, AXONAL, B, Brain/spinal, CORD, INJURY, NB1JXX, NB1XXX, NBXXXX, NXXXXX, PROMOTES, Regeneration

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Neurology

Small Molecule MRS5474 with Anticonvulsant Activity for Treatment of Epilepsy

Adenosine modulates many physiological processes by activating specific adenosine receptors. These adenosine receptors play a critical role in the regulation of cellular signaling and are broadly distributed throughout the body. Thus, the ability to modulate adenosine receptor-mediated signaling is an attractive therapeutic strategy for a broad range...

Published: 7/25/2024 | Inventor(s): Dilip Tosh, Kenneth Jacobson

Keywords(s): A3, Activity, ADENOSINE, AGONISTS, Agonists:, Al, ANTAGONISTS, Anticonvulsant, Derivatives, Docking, IB1FXX, IB1XXX, IBXXXX, IXXXXX, NB1EXX, NB1HXX, NB1XXX, NBXXXX, N-Methanocarba, Nucleosides, NXXXXX, PARTIAL, Patent Category - Chemistry, POTENT, RECEPTOR, TRUNCATED

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Neurology, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Cardiology, Application > Therapeutics

Cyclodextrins as Therapeutics for Lysosomal Storage Disorders

Cyclodextrins (CD), alone or in combination with other agents (e.g., vitamin E), as therapeutics for the treatment of lysosomal storage disorders (LSDs) caused by the accumulation of non-cholesterol lipids. CDs are sugar molecules in a ring form. The alpha-CD (6 sugars), beta-CD (7 sugars) and gamma-CD (8 sugars) are commonly used cyclodextrins. The...

Published: 7/25/2024 | Inventor(s): Wei Zheng, Miao Xu, Manju Swaroop, Juan Marugan, John McKew

Keywords(s): Combination, CYCLODEXTRIN, DISEASES, e, IB6XXX, IBXXXX, IXXXXX, Lysosomal, NB1JXX, NB1XXX, NBXXXX, NXXXXX, Storage, treatment, UA1XXX, USES, Vitamin

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Rare / Neglected Diseases, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Reproductive Health

Therapeutic Approach to Neurodegenerative Disorders Using a TFP5-Peptide

This invention discloses methods for treating neurodegenerative diseases by administering cyclin dependent kinase 5 (Cdk5) inhibitory peptides derived from P35, the activator of Cdk5. Abnormally hyperactive Cdk5 has been shown to be associated with a variety of neurodegenerative disorders. Disclosed in this invention are isolated peptide fragments,...

Published: 7/25/2024 | Inventor(s): Harish (Estate of) Pant

Keywords(s): Approach, DISORDERS, NB1BXX, NB1FXX, NB1XXX, NBXXXX, NEURODEGENERATIVE, NXXXXX, TFP5-peptide, therapeutic

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Neurology

Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin

The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood...

Published: 4/8/2024 | Inventor(s): Jacqueline Shukaliak-Quandt

Keywords(s): ANIMAL, Autoimmune, BBXXXX, BCXXXX, brain, Damage, EAE, Encephalomylelitis, e-selectin, EXPERIMENTAL, IMMUNOLOGICAL, Model, Multiple sclerosis, NB1HXX, NB1JXX, NB1XXX, NBXXXX, NXXXXX, PREVENTS, Tolerization

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology

AAV5 Vector for Transducing Brain Cells and Lung Cells

The invention described and claimed in this patent application is related to the delivery of heterologous nucleic acids or genes to particular target cells. In particular, the application relates to methods of delivering a heterologous nucleic acid or gene of interest to particular target cells using an Adeno-Associated Virus of serotype 5 (AAV5)....

Published: 7/25/2024 | Inventor(s): Beverly Davidson, Robert Kotin, Joseph Zabner, John (Jay) Chiorini

Keywords(s): AAV, AAV5, brain, CB2AXX, CBXXXX, CXXXXX, GB2A2X, GB2XXX, GENE THERAPY, IB4XXX, IBXXXX, IXXXXX, Listed LPM Reichman as of 4/15/2015, LUNG, NB1XXX, NBXXXX, NXXXXX, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SACGHS DNA Patent Initial Set, USES, Vector, viral vector

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Pulmonology, TherapeuticArea > Oncology, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics, Application > Therapeutics

1 2

|

|

|

© 2024. All Rights Reserved. Powered by Inteum